PMC:7073332 / 39863-40613 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1109","span":{"begin":566,"end":571},"obj":"Species"}],"attributes":[{"id":"A1109","pred":"tao:has_database_id","subj":"1109","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Building the drug–target network\nHere, we collected drug–target interaction information from the DrugBank database (v4.3)86, Therapeutic Target Database (TTD)87, PharmGKB database, ChEMBL (v20)88, BindingDB89, and IUPHAR/BPS Guide to PHARMACOLOGY90. The chemical structure of each drug with SMILES format was extracted from DrugBank86. Here, drug–target interactions meeting the following three criteria were used: (i) binding affinities, including Ki, Kd, IC50, or EC50 each ≤10 μM; (ii) the target was marked as “reviewed” in the UniProt database91; and (iii) the human target was represented by a unique UniProt accession number. The details for building the experimentally validated drug–target network are provided in our recent studies13,23,28."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T160","span":{"begin":221,"end":224},"obj":"Disease"}],"attributes":[{"id":"A160","pred":"mondo_id","subj":"T160","obj":"http://purl.obolibrary.org/obo/MONDO_0009901"}],"text":"Building the drug–target network\nHere, we collected drug–target interaction information from the DrugBank database (v4.3)86, Therapeutic Target Database (TTD)87, PharmGKB database, ChEMBL (v20)88, BindingDB89, and IUPHAR/BPS Guide to PHARMACOLOGY90. The chemical structure of each drug with SMILES format was extracted from DrugBank86. Here, drug–target interactions meeting the following three criteria were used: (i) binding affinities, including Ki, Kd, IC50, or EC50 each ≤10 μM; (ii) the target was marked as “reviewed” in the UniProt database91; and (iii) the human target was represented by a unique UniProt accession number. The details for building the experimentally validated drug–target network are provided in our recent studies13,23,28."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T276","span":{"begin":566,"end":571},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T277","span":{"begin":598,"end":599},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Building the drug–target network\nHere, we collected drug–target interaction information from the DrugBank database (v4.3)86, Therapeutic Target Database (TTD)87, PharmGKB database, ChEMBL (v20)88, BindingDB89, and IUPHAR/BPS Guide to PHARMACOLOGY90. The chemical structure of each drug with SMILES format was extracted from DrugBank86. Here, drug–target interactions meeting the following three criteria were used: (i) binding affinities, including Ki, Kd, IC50, or EC50 each ≤10 μM; (ii) the target was marked as “reviewed” in the UniProt database91; and (iii) the human target was represented by a unique UniProt accession number. The details for building the experimentally validated drug–target network are provided in our recent studies13,23,28."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T445","span":{"begin":13,"end":17},"obj":"Chemical"},{"id":"T446","span":{"begin":52,"end":56},"obj":"Chemical"},{"id":"T447","span":{"begin":154,"end":157},"obj":"Chemical"},{"id":"T448","span":{"begin":281,"end":285},"obj":"Chemical"},{"id":"T449","span":{"begin":342,"end":346},"obj":"Chemical"},{"id":"T450","span":{"begin":687,"end":691},"obj":"Chemical"}],"attributes":[{"id":"A445","pred":"chebi_id","subj":"T445","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A446","pred":"chebi_id","subj":"T446","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A447","pred":"chebi_id","subj":"T447","obj":"http://purl.obolibrary.org/obo/CHEBI_73659"},{"id":"A448","pred":"chebi_id","subj":"T448","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A449","pred":"chebi_id","subj":"T449","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A450","pred":"chebi_id","subj":"T450","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"Building the drug–target network\nHere, we collected drug–target interaction information from the DrugBank database (v4.3)86, Therapeutic Target Database (TTD)87, PharmGKB database, ChEMBL (v20)88, BindingDB89, and IUPHAR/BPS Guide to PHARMACOLOGY90. The chemical structure of each drug with SMILES format was extracted from DrugBank86. Here, drug–target interactions meeting the following three criteria were used: (i) binding affinities, including Ki, Kd, IC50, or EC50 each ≤10 μM; (ii) the target was marked as “reviewed” in the UniProt database91; and (iii) the human target was represented by a unique UniProt accession number. The details for building the experimentally validated drug–target network are provided in our recent studies13,23,28."}

{"project":"LitCovid-sentences","denotations":[{"id":"T248","span":{"begin":0,"end":32},"obj":"Sentence"},{"id":"T249","span":{"begin":33,"end":249},"obj":"Sentence"},{"id":"T250","span":{"begin":250,"end":335},"obj":"Sentence"},{"id":"T251","span":{"begin":336,"end":632},"obj":"Sentence"},{"id":"T252","span":{"begin":633,"end":750},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Building the drug–target network\nHere, we collected drug–target interaction information from the DrugBank database (v4.3)86, Therapeutic Target Database (TTD)87, PharmGKB database, ChEMBL (v20)88, BindingDB89, and IUPHAR/BPS Guide to PHARMACOLOGY90. The chemical structure of each drug with SMILES format was extracted from DrugBank86. Here, drug–target interactions meeting the following three criteria were used: (i) binding affinities, including Ki, Kd, IC50, or EC50 each ≤10 μM; (ii) the target was marked as “reviewed” in the UniProt database91; and (iii) the human target was represented by a unique UniProt accession number. The details for building the experimentally validated drug–target network are provided in our recent studies13,23,28."}

{"project":"2_test","denotations":[{"id":"32194980-24203711-19614251","span":{"begin":121,"end":123},"obj":"24203711"},{"id":"32194980-26578601-19614252","span":{"begin":158,"end":160},"obj":"26578601"},{"id":"32194980-21948594-19614253","span":{"begin":193,"end":195},"obj":"21948594"},{"id":"32194980-17145705-19614254","span":{"begin":206,"end":208},"obj":"17145705"},{"id":"32194980-24234439-19614255","span":{"begin":246,"end":248},"obj":"24234439"},{"id":"32194980-24203711-19614256","span":{"begin":332,"end":334},"obj":"24203711"},{"id":"32194980-14681372-19614257","span":{"begin":548,"end":550},"obj":"14681372"},{"id":"32194980-30002366-19614258","span":{"begin":741,"end":743},"obj":"30002366"},{"id":"32194980-31375661-19614259","span":{"begin":744,"end":746},"obj":"31375661"},{"id":"32194980-30867426-19614260","span":{"begin":747,"end":749},"obj":"30867426"}],"text":"Building the drug–target network\nHere, we collected drug–target interaction information from the DrugBank database (v4.3)86, Therapeutic Target Database (TTD)87, PharmGKB database, ChEMBL (v20)88, BindingDB89, and IUPHAR/BPS Guide to PHARMACOLOGY90. The chemical structure of each drug with SMILES format was extracted from DrugBank86. Here, drug–target interactions meeting the following three criteria were used: (i) binding affinities, including Ki, Kd, IC50, or EC50 each ≤10 μM; (ii) the target was marked as “reviewed” in the UniProt database91; and (iii) the human target was represented by a unique UniProt accession number. The details for building the experimentally validated drug–target network are provided in our recent studies13,23,28."}